Legal & General Group Plc grew its stake in The Medicines Company (NASDAQ:MDCO) by 3.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 159,914 shares of the company’s stock after purchasing an additional 5,835 shares during the period. Legal & General Group Plc owned about 0.22% of The Medicines worth $3,050,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the business. Piedmont Investment Advisors Inc. raised its stake in shares of The Medicines by 3.4% during the 4th quarter. Piedmont Investment Advisors Inc. now owns 15,698 shares of the company’s stock worth $300,000 after buying an additional 517 shares during the period. State of Alaska Department of Revenue raised its stake in shares of The Medicines by 3.2% during the 4th quarter. State of Alaska Department of Revenue now owns 22,020 shares of the company’s stock worth $421,000 after buying an additional 681 shares during the period. First Mercantile Trust Co. raised its stake in shares of The Medicines by 21.6% during the 4th quarter. First Mercantile Trust Co. now owns 3,965 shares of the company’s stock worth $76,000 after buying an additional 705 shares during the period. Bank of Montreal Can raised its stake in shares of The Medicines by 31.9% during the 4th quarter. Bank of Montreal Can now owns 3,139 shares of the company’s stock worth $59,000 after buying an additional 760 shares during the period. Finally, United Services Automobile Association raised its stake in shares of The Medicines by 0.3% during the 4th quarter. United Services Automobile Association now owns 392,724 shares of the company’s stock worth $7,517,000 after buying an additional 1,020 shares during the period.

In other news, Director Alexander J. Denner acquired 325,000 shares of The Medicines stock in a transaction that occurred on Monday, March 4th. The stock was purchased at an average cost of $25.45 per share, with a total value of $8,271,250.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Alexander J. Denner acquired 248,100 shares of The Medicines stock in a transaction that occurred on Wednesday, March 6th. The stock was purchased at an average cost of $24.91 per share, with a total value of $6,180,171.00. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 673,100 shares of company stock valued at $16,966,421. 10.29% of the stock is owned by corporate insiders.

Several research analysts have recently weighed in on the company. Robert W. Baird assumed coverage on The Medicines in a research note on Wednesday, March 27th. They set an “outperform” rating and a $80.00 target price for the company. Zacks Investment Research raised The Medicines from a “sell” rating to a “hold” rating in a research note on Monday, December 31st. BidaskClub raised The Medicines from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. Finally, Roth Capital initiated coverage on The Medicines in a research note on Thursday, March 21st. They set a “buy” rating and a $75.00 target price for the company. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $53.13.

NASDAQ MDCO opened at $28.19 on Tuesday. The Medicines Company has a one year low of $16.69 and a one year high of $41.57.

The Medicines (NASDAQ:MDCO) last posted its quarterly earnings data on Wednesday, February 27th. The company reported ($0.67) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.09). During the same quarter in the previous year, the business earned ($0.61) earnings per share. Analysts anticipate that The Medicines Company will post -2.51 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Legal & General Group Plc Buys 5,835 Shares of The Medicines Company (MDCO)” was published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2019/04/16/legal-general-group-plc-buys-5835-shares-of-the-medicines-company-mdco.html.

The Medicines Company Profile

The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.

Further Reading: What is the 52-week high/low?

Institutional Ownership by Quarter for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.